PE20220333A1 - Farmaco y metodo para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco - Google Patents
Farmaco y metodo para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmacoInfo
- Publication number
- PE20220333A1 PE20220333A1 PE2021001508A PE2021001508A PE20220333A1 PE 20220333 A1 PE20220333 A1 PE 20220333A1 PE 2021001508 A PE2021001508 A PE 2021001508A PE 2021001508 A PE2021001508 A PE 2021001508A PE 20220333 A1 PE20220333 A1 PE 20220333A1
- Authority
- PE
- Peru
- Prior art keywords
- drug
- treat
- prevent diabetes
- diabetes complications
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 | ||
| PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220333A1 true PE20220333A1 (es) | 2022-03-14 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001508A PE20220333A1 (es) | 2019-03-12 | 2020-03-12 | Farmaco y metodo para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| WO2022171151A1 (zh) * | 2021-02-10 | 2022-08-18 | 上海森辉医药有限公司 | 一种smtp-7衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| JP4313049B2 (ja) * | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| US20090270476A1 (en) | 2005-10-06 | 2009-10-29 | Keiji Hasumi | Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof |
| WO2007111203A1 (ja) | 2006-03-27 | 2007-10-04 | Tokyo University Of Agriculture And Technology Tlo Co., Ltd. | トリプレニルフェノール化合物及びトリプレニルフェノール化合物の製造方法並びに、血栓溶解促進剤 |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| US9078880B2 (en) * | 2009-07-06 | 2015-07-14 | National University Corporation Tokyo University Of Agriculture And Technology | Cytoprotective agent |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en active Pending
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja unknown
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko unknown
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt unknown
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220009371A (ko) | 2022-01-24 |
| US20220218664A1 (en) | 2022-07-14 |
| IL286289A (en) | 2021-10-31 |
| SG11202109982YA (en) | 2021-10-28 |
| WO2020184691A1 (ja) | 2020-09-17 |
| EP3939659A4 (en) | 2022-12-21 |
| EP3939659A1 (en) | 2022-01-19 |
| EA202192483A1 (ru) | 2021-12-24 |
| BR112021018084A8 (pt) | 2022-10-04 |
| JPWO2020184691A1 (US07534539-20090519-C00280.png) | 2020-09-17 |
| CN114126711A (zh) | 2022-03-01 |
| BR112021018084A2 (US07534539-20090519-C00280.png) | 2021-12-21 |
| CA3133204A1 (en) | 2020-09-17 |
| CL2021002373A1 (es) | 2022-06-17 |
| AU2020238177A1 (en) | 2021-11-04 |
| MX2021011007A (es) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020004249A2 (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| SV2017005384A (es) | Compuestos aminopirimidinilo | |
| BR112017007708A2 (pt) | composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente | |
| UY38428A (es) | Nuevos compuestos antihelmínticos | |
| PE20220333A1 (es) | Farmaco y metodo para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| MX2021003999A (es) | Moleculas de bajo peso molecular degradadoras de la proteina mdm2. | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| PE20211780A1 (es) | Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp) | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2019012285A (es) | Metodos de tratamiento de encefalopatias del desarrollo. | |
| BR112017023164A2 (pt) | composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo | |
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
| BR112023023578A2 (pt) | Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda | |
| CY1124577T1 (el) | Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης | |
| CO2019010663A2 (es) | Composición de carbohidratos para la diálisis | |
| CO5611129A2 (es) | Co-terapia con oxazolidinona | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas |